Real-World Studies
Zanubrutinib Linked to Longer Time to Discontinuation Than Acalabrutinib in CLL/SLL
Ayati et alOncology and Therapy
A retrospective cohort study evaluated real-world treatment patterns and clinical outcomes among 481 adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) receiving monotherapy with second-generation Bruton tyrosine kinase inhibitors (BTKis) across the University of California Health system between January 1, 2021, and November 30, 2025. The cohort included 175 patients treated with zanubrutinib and 306 treated with acalabrutinib, with a median follow-up of 30.7 months.
Median real-world time to treatment discontinuation (TTD) was significantly longer in patients receiving zanubrutinib compared with those receiving acalabrutinib (31.8 months vs. 14.4 months; P = 0.002). This difference remained statistically significant in both unadjusted analyses (hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.51–0.86) and adjusted multivariate analyses (HR 0.74, 95% CI 0.56–0.98). In multivariate modeling, higher comorbidity burden was significantly associated with shorter TTNT and OS.
In an exploratory subgroup analysis utilizing a large language model to extract safety data from unstructured electronic health records, overall adverse event rates (grades unspecified) were similar across both cohorts. However, specific toxicity profiles differed: fatigue, bruising, and rash were significantly more frequent in the zanubrutinib group, whereas headache was significantly more frequent in the acalabrutinib group. For both agents, the leading causes of discontinuation were adverse events and disease progression.
Key Takeaways
- Median real-world time to treatment discontinuation was significantly longer with zanubrutinib compared to acalabrutinib (31.8 vs. 14.4 months; unadjusted HR 0.66, 95% CI 0.51–0.86; adjusted HR 0.74, 95% CI 0.56–0.98; P = 0.002).
- Time to next treatment and overall survival did not significantly differ between cohorts, although both outcomes were significantly shorter in patients with an increasing comorbidity burden.
- Overall adverse event rates were similar between groups, but fatigue, bruising, and rash were significantly more common with zanubrutinib, whereas headache was significantly more common with acalabrutinib.
Read the original sourceOncology and Therapy
